Anhui Anke Biotechnology (Group) (300009) Fundamentals 2026 — P/E 19.8x, Revenue Analysis | SniperIQ
Anhui Anke Biotechnology (Group) (300009) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥13.8B, trading at ¥8.26 on the SHZ. This SniperIQ fundamentals page covers Anhui Anke Biotechnology (Group)'s valuation (P/E 19.8x, P/B 2.9x), profitability (net margin 27.1%), revenue (¥2.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Anhui Anke Biotechnology (Group)'s market cap?
Anhui Anke Biotechnology (Group) (300009) has a market capitalization of approximately ¥13.8B, trading at ¥8.26 on the SHZ. Market cap moves with the live share price.
What is Anhui Anke Biotechnology (Group)'s P/E ratio?
Anhui Anke Biotechnology (Group)'s trailing twelve-month P/E ratio is 19.8x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Anhui Anke Biotechnology (Group)?
Anhui Anke Biotechnology (Group) runs a net profit margin of 27.1%, a gross margin of 75.2%, and an operating margin of 30.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Anhui Anke Biotechnology (Group) generate?
Anhui Anke Biotechnology (Group) reported revenue of ¥2.6B for fiscal year 2025, with net income of ¥735M and earnings per share (EPS) of 0.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Anhui Anke Biotechnology (Group) pay a dividend?
Anhui Anke Biotechnology (Group) offers a trailing dividend yield of about 3.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Anhui Anke Biotechnology (Group) financially healthy?
Anhui Anke Biotechnology (Group) carries a debt-to-equity ratio of 0.01x and a current ratio of 4.30x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Anhui Anke Biotechnology (Group) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Anhui Anke Biotechnology (Group) (300009) the key facts are: market cap ¥13.8B, P/E 19.8x, revenue ¥2.6B, 52-week range 7.35-13.06. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Anhui Anke Biotechnology (Group)'s full fundamentals live
Get Anhui Anke Biotechnology (Group)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.